Fadeucravacitinib vs TQH3906
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
Fadeucravacitinib
Developed by Beijing InnoCare Pharma Tech Co.
NCT06109818 · Phase 2 · completed
The trial randomized 129 participants to two ICP-488 dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical psoriasis measure PASI 75 at Week 12, but the registry does not report whether the comparison was met.
Figures via dermatology news coverage of the sponsor's announcement; no peer-reviewed publication or registry results yet. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Percentage of subjects who achieved a PASI 75 response (a reduction of minimum 75% from baseline in PASI score) at Week 12. (Baseline up to Week 12): PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved (met)
Result source: NCT06109818
TQH3906
Developed by Sino Biopharmaceutical
NCT06542614 · Phase 2 · completed
This Phase 2 trial randomly assigned 209 people with plaque psoriasis to TQH3906 or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was the proportion reaching PASI 75, a 75% improvement in psoriasis severity, at week 12. The sponsor reports more than 90% reaching PASI 75 and more than 70% reaching PASI 90 at the recommended dose, but gives no placebo figure and no statistical comparison, so the size of the advantage over placebo is not established by what has been released.
Next expected readout: September 2027 · NCT07724366 (registry estimate)
Reported efficacy
Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 at week 12 (Up to week 12): At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks (met)
Result source: NCT06542614
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Fadeucravacitinib | TQH3906 |
|---|---|---|
| PASI 75 | —Trial running · NCT06842199 | —Trial running · NCT07724366 |
| PASI 90 | —Trial running · NCT06842199 | —Trial running · NCT07724366 |
| PASI 100 | —Trial running · NCT06842199 | —Trial running · NCT07724366 |
| sPGA 0/1 | —Trial running · NCT06842199 | —Trial running · NCT07724366 |
| DLQI, change | —Trial running · NCT06842199 | —Trial running · NCT07724366 |
PASI 75
- Fadeucravacitinib
- —Trial running · NCT06842199
- TQH3906
- —Trial running · NCT07724366
PASI 90
- Fadeucravacitinib
- —Trial running · NCT06842199
- TQH3906
- —Trial running · NCT07724366
PASI 100
- Fadeucravacitinib
- —Trial running · NCT06842199
- TQH3906
- —Trial running · NCT07724366
sPGA 0/1
- Fadeucravacitinib
- —Trial running · NCT06842199
- TQH3906
- —Trial running · NCT07724366
DLQI, change
- Fadeucravacitinib
- —Trial running · NCT06842199
- TQH3906
- —Trial running · NCT07724366
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fadeucravacitinib's landscape · TQH3906's landscape